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Microarray technology has been used extensively in biological and medical studies to monitor thousands of genes at the expression level across the genome. Typically, statistical analysis for microarray calculates p-values for each gene based on a statistical test first, and then applies multiple comparison methods to adjust the nominal p-values. When many significant genes are selected, it is often difficult to interpret the results in biological context. On the other hand, due to the large number of genes tested, it may also be possible that too few significant genes are left after adjusting for multiple comparisons. Gene Set Analysis tests for expression changes in groups of related genes in microarray data, such as those defined by gene annotation databases Gene Ontology (Ashburner et al. 2000) and KEGG Pathway (Kanehisa et al. 2000) . In additional to facilitate interpretation of results, gene set analysis also increases power by combining weak signals from a number of individual genes in the group.
Software packages such as GENMAPP (Dahlquist et al. 2002) , CHIPINFO, ONTO-TOOLS (Draghici et al. 2003) , GOstat (Beibbarth et al. 2004) , DAVID (Dennis et al. 2003) , WebGestalt , GOTM (Zhang et al.2004) , JMP Genomics (http://www.jmp.com/genomics) and GeneTrail ) use various approaches to test for overrepresentation of significant genes that belong to a gene set. A full discussion of the methods and a detailed comparison of these tools can be found in Khatri and Draghici (2005) . Rivals (2007) discussed different sampling designs that can lead to the hypergeometric null distribution and details on the implementation of the methods. Despite its popularity, there are a number of limitations with overrepresentation analysis: the assumption that genes are independent may not hold for tightly co-regulated gene sets; the selection of significant genes is often based on an arbitrary cutoff; and information is lost by not using continuous information in p-values.
One method that uses the continuous distribution of p-values is the GSEA method (Mootha et al. 2003 , Subramanian et al. 2005 . GSEA makes statistical inference by permuting sample labels, thus
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preserving correlation structure among genes. Some extensions of the GSEA method include GSA (Efron and Tibshirani 2007) , SAM-GS (Dinu et al. 2007 ), GSEA via dynamic programming , GSEAlm (Jiang et al., 2007) . Other permutationbased methods include SAFE (Barry, 2005) , multivariate Nstatistic (Klebanov et al, 2007) and others. Some recently proposed parametric methods that do not rely on permutation test include PAGE (Kim and Volsky, 2005) , GlobalTest (Goeman et al. 2004 (Goeman et al. , 2005 , GlobalANCOVA (Hummel et al. 2008 ), Mixed models (Wang et al. 2008 ) and others.
Most of the aforementioned algorithms had been presented as tests for association of gene sets with binary outcomes. In practice, microarray experiments may also have continuous outcome for quantative traits such as lesion score or body weight. In the field of cancer research, the outcome is often survival time or time to death, to avoid arbitrary cutoff such as 10 years survival, the analysis needs to account for censored observations. Censoring occurs for example when the patient survived over the entire study period or were lost to follow up, in these cases, we only know partial information on the outcome. One way to analyze microarray dataset with survival outcome using Fisher's exact test is to fit Cox regression model for each gene (with its gene expression value as predictor) and then use a predetermined cutoff (e.g. p-value < 0.05) based on p-values from Cox model as threshold for declaring differential gene expression. Similarly, GSEA can also be adapted for microarray experiments with continuous or survival outcome by using linear regression or Cox regression model instead of tstatistics to obtain local statistics for each gene. However, the performance and properties of these tests for continuous or survival outcomes had not been adequately studied.
In this paper, we propose a new gene set analysis method for testing association between sets of genes with continuous or survival outcomes. We evaluate its performance and compare it to performance of tests in currently available tools such as Fisher's exact test, GSEA and extensions of GSEA. In addition, we illustrate this new method using data from two microarray experiments with lesion score and survival outcomes. This new method extends methods in Tomfohr et al. (2005) , Bair et al. (2004) and Bair et al. (2006) . Tomfohr et al. (2005) performed PCA (Principal Component Analysis) on gene expression values from a priori defined gene set, estimated correlation statistic between continuous outcome and the first principal component, and then tested association between gene sets and outcome using a permutation test. Although PCA is an effective method for reducing high dimensionality and capture variations in gene expression values (Alter et al. 2000) , one limitation is that the latent variable identified by the first principal component may be unrelated to outcome.
Instead of performing PCA on all genes, Bair et al. (2004) and Bair et al. (2006) proposed Supervised PCA (SPCA) method, which estimated principal components from a selected subset of genes. Because outcome values were used to select the subset of genes, this procedure is supervised, and thus called Supervised Principal Component Analysis (SPCA). The SPCA method was shown to be an effective algorithm for classification of survival and continuous outcomes using gene expression data. The estimation of principal components from a selected subset of genes significantly improved prediction accuracy in SPCA algorithm compared to the PCA algorithm without the gene screening step. Similarly, in the classification of biological samples setting, Dai et al. (2006) showed partial least squares and sliced inverse regression, which uses outcome information to construct predictors, performed better than unsupervised PCA in terms of prediction accuracy.
In this paper, we extend the SPCA method to gene set analysis setting to test for significant association of a gene set with outcome. In Bair (2004) , the subset of genes used to estimate latent variable was selected from all the genes on a microarray. In contrast, here we select subset of genes from an a priori defined group of genes, for example those with the same GO term. A linear model with principal component score constructed with the selected genes as predictor (see details in Section 2.2) is then used to test for association between gene set and outcome. Because of the step to select subset of genes, the resulting test statistics for regression coefficient in the proposed linear model can no longer be approximated well using t distribution, to account for this, we propose a mixture model of extreme values to approximate distributions of the test statistic. The details of the proposed mixture model and Supervised PCA for testing association between gene set and outcome are discussed in Section 2. In Section 3.1, we show that this method performs favorably compared to the unsupervised PCA model, Fisher's test, GSEA and its extension GSEAlm for gene set analysis using simulated data. The proposed SPCA model provides the ability to model and borrow strength across genes that are both up and down in a gene set. In addition, it operates in a well-established statistical framework and can handle design information such as covariate adjustment, matching information, and testing for interaction of effects. In Sections 3.2 and 3.3, we illustrate the SPCA model using real microarray datasets with continuous outcome lesion score and survival outcome time to metastasis of cancer. In section 4, we provide some concluding comments.
METHODS

Principal Component Analysis
Consider a gene set with p genes, let (Jolliffe, 2002 
. Therefore, SVD provides not only the coefficients and standard deviations for the PCs with L and A matrices, but also the PC scores of each observation with matrix UL. For simple models, it can be shown that the principal components provide an optimal approximation to the original variables (Jolliffe, 2002) .
Supervised PCA Model
The assumption behind the Supervised PCA model is that given an a priori defined group of genes, only a subset of these genes is associated with a latent variable, which then varies with outcome. This assumption is based on the fact that because gene sets are defined a priori and are biological context free, when they are put into a specific biological context such as those in a microarray study (e.g. a specific tissue type or a specific disease), typically only a subset of genes from the gene set is responsible for the corresponding cellular process.
Because the subset of genes is selected using outcome information (see details below), SPCA is a supervised procedure. Biologically, a subset of genes from an a priori defined gene set, each contributing a different amount, work together to bring about changes in a cellular process, and this cellular process then relates to variations in phenotype. Therefore, our objective is to select the subset of relevant genes, estimate latent variable associated with underlying cellular process, and assess statistical significance of association between latent variable and outcome. To this end, we propose the following Supervised PCA model:
Here, j Y is outcome value for jth sample, PC1 is the first principal component score estimated from selected subset of genes in a predefined gene set G, it represents the latent variable for the underlying biological process associated with this group of genes. Magnitude of loadings for the first principal component score can be viewed as an estimate of the amount of contributions from different genes. In the literature, the first principal component score has also been called "eigengene" (Alter et al. 2000) . With Model 1, statistical significance of 1 β would indicate significant association between gene set G and outcome.
Given a set of gene expression values
for an a priori defined gene set, the selection for the subset of relevant genes can be accomplished in several steps: So for the n threshold values, we have n t statis-
and we choose the subset of genes corresponding to threshold M.
Significance Testing
Without the gene selection process, when all the genes in an a priori defined gene set are included in analysis, the test statistic 
can no longer be approximated well using tdistribution. We next show the distribution of M follows a two-component mixture distribution based on Gumbel extreme value distributions.
The Gumbel extreme value distributions model maximum or minimum of a set of random variables. More specifically, given a set of random variables 1 { ,..., } n T T , under regularity conditions (Leadbetter et al. 1982) 
(the test statistic in step 4 of Section 2.2), and let p = Pr( 0) M > , then the distribution function for M can then be approximated as
The conditioning argument in the third line above follows because if M is positive, then M must be the maximum of all standardized regression coefficients { ; 1,..., } The corresponding density function for M is then Benjamini and Hochberg (1995) . An adjusted p-value of 0.05 for a gene set indicates that among all significant gene sets selected at this threshold, 5 out 100 of them are expected to be false leads.
RESULTS
Simulation Study
We performed a simulation study to assess the sensitivity and specificity of the Supervised PCA model compared with PCA, Fisher's exact test, GSEA and GSEAlm methods. For each scenario in Table 1 , we first generated 50 phenotype scores, corresponding to 50 samples, from normal distribution with mean 1 and standard deviation 1. Next, for each sample, we generated 2500 gene expression values from the standard normal distribution.
These gene values were then assigned to 50 gene-sets, each with 50 genes. For gene-set 1, treatment effects for a subset of genes (n_genes in Table 1) Therefore, for each scenario in Table 1 , by design of the experiment, only the first gene-set was associated with phenotype and the other gene-sets were null gene-sets. There were 12 (=2 x 2 x 3) scenarios: the numbers of genes in gene-set 1 with treatment effects added were 5 or 10 genes; r µ (mean for i r ) = 0.1, 0.2; 2 r σ (variance for i r ) = 0.5, 1, 1.5; and the standard deviation for noise ij ε was set to be 3.
τ =
To compare the performances of SPCA, PCA, Fisher's exact test, GSEA, GSEAlm algorithms, for each scenario, we generated 20 datasets, each with 2500 gene expression values and 50 phenotype scores as described above. For each method, using gene sets from all 20 datasets (49 x 20 = 980 control gene sets, and 1 x 20 = 20 gene sets associated with outcome), we computed Receiver Operator Characteristics (ROC) curves which show the trade-off between sensitivity and 1-specificity as the threshold for declaring significant gene set was varied. To compare the overall discriminative abilities of the methods over all possible cutoffs, we calculated the area under the ROC curve (AUC). In addition, to compare sensitivity of the methods, we calculated the mean of p-values for gene-set 1.
The javaGSEA implementation was used for GSEA analysis, we chose "Pearson correlation" (between expression values and phenotype scores) as the metric for ranking genes and 200 permutations were applied to phenotype labels. For Supervised PCA, unsupervised PCA, GSEAlm and Fisher's exact test methods, we used R packages (http://www.r-project.org/) superpc (with modification), lm, GSEAlm, and fisher.test.
In terms of AUC, the results in Table 1 show that the SPCA model outperformed the PCA and GSEA models consistently Table 1 . Fisher (0.05) = Fisher's exact test, using FDR 0.05 as significance cutoff for differential expression of single genes. Fisher (0.1) = Fisher's exact, using FDR 0.1 as significance cutoff for differential expression of single genes. There were 20 simulated datasets, each dataset has 2500 genes assigned to 50 gene sets, among them only the first gene set include genes associated with outcome by design. See text for details of simulation experiment. across all scenarios, especially when the variance of i r is small. Pvalues for gene-set 1 from the SPCA model were smaller than the other methods for all scenarios indicating higher sensitivity for this method. GSEAlm which tested mean shift of i r from zero for genes from each gene set did not perform well, probably because signals from up-regulated genes with positive i r canceled signals from down-regulated genes with negative i r . In contrast, the good performance from SPCA method shows this method can be used to effectively model reverse regulations in gene sets where both up and down regulated genes are expected. Figure 1 shows the ROC curves for the six methods for scene 7 in Table 1 . Fisher's exact tests showed very good specificity: for example, when FDR 0.05 was used as threshold for selecting significant genes, for 980 null gene sets, Fisher's exact test estimated gene set p-values to be 1 for all gene sets except one gene set with p-value 0.04. Therefore, the probability of false positive, or 1-Specificity, based on null gene sets, had only 3 values: 0, 1/980 and 1. The points with false positive rate 1/980 and 1 were connected using a straight dotted line. Similar behavior was observed for Fisher's exact test with FDR 0.1 as threshold. On the other hand, because of this conservativeness, sensitivity for Fisher's exact test is also compromised. Figure 1 shows among all methods, SPCA method had the best sensitivities across all levels of specificity.
Breast Cancer Dataset
We applied the SPCA, GSEA and Fisher's exact test to data from a breast cancer microarray experiment (Wang et al. 2005) . In this experiment, tumor samples from 286 patients with lymph-nodenegative breast cancer were collected. These patients were treated with surgery or radiotherapy over an 11 yeas period. The outcome of this study is time to metastasis, and our objective was to identify gene sets associated with this survival outcome. To avoid arbitrary cutoff such as 5 year relapse-free, and to account for patients who were lost to follow-up, we used Cox regression models from survival analysis instead of logistic regression to obtain local statistics for SPCA, GSEA and Fisher's exact methods, see details below.
The expression data with 22283 transcripts were obtained from Affymetrix U133a GeneChip platform (GEO Accession No. GSE2034). We first mapped these transcripts to EntrezGene ID and then associated them with GO Biological Process categories. In order to reduce the redundancy in GO, we further removed all child-categories if corresponding parent-category was within the size limitation between 5 and 300. After these steps we were left with 11609 genes and 372 GO categories.
For GSEA method, we first applied Cox proportional hazards regression model to each gene, with time to metastasis as outcome and gene expression value as predictor. Next, all genes were ranked according to standardized regression coefficient from this Cox model, and this ranked gene list was then used for GSEA "Pre-ranked" algorithm. Finally, 200 permutations were applied to sample labels to test if genes from each a priori defined GO gene sets were randomly distributed along the ranked gene list. Similarly, for Fisher's exact test, we applied Cox model to each gene, used FDR 0.1 as significance level cutoff to set up the two by two tables, and calculated p-values for each gene set based on hypergeometric distribution.
For the SPCA method, to generate null distribution for
where k T is standardized regression coefficient using the selected subset of genes (See Section 2 for details), we assumed Weibull distribution for the survival outcome time to metastasis and estimated shape and scale parameters by fitting observed outcomes from 286 patients with censoring status to intercept only Weibull survival regression model. Based on these estimated shape and scale parameters, for each gene set, we next generated a set of pseudo survival outcomes from Weibull distribution. To account for censoring, each patient was randomly chosen to have censored outcome according to the estimated censoring proportion from observed outcomes. Next, with these generated pseudo outcomes, we applied steps 1-4 in section 2.2 to each gene set. The resulting test statistics for M were then pooled from all gene sets to obtain null distributions of M . The parameters  for mixture model   1  2  1  2 , , , , p µ µ σ σ were then estimated from this null distribution. Finally, using observed outcomes, for each gene set, we estimated p-values for test statistics in Model 1 based on this null distribution, as discussed in Section 2.3. For all methods, once nominal p-values were calculated, the adjusted p-values were then computed using R multtest procedure to control False Discovery Rate (FDR) using the method of Benjamini and Hochberg (1995) .
The 10 most significant GO terms found by SPCA and GSEA are listed in Tables 2 and 3 . At FDR 0.1 level, GSEA identified "translation" as the only significant GO term. For Fisher's exact test, the lowest adjusted p-value was 0.2337 for "cell motility". In contrast, SPCA identified additional 39 significant GO terms at FDR 0.1 level besides "translation". In agreement with our simulation study, these results show that power for gene set analysis can be improved for GSEA and Fisher's exact test using SPCA method. Table 3 . Ten most significant GO terms by GSEA analysis of breast cancer dataset. We next examined overlap of our analysis results with previous published results. Wang et al (2005) identified a 76-gene signature for predicting tumor metastasis. These genes were selected by fitting Cox's proportional hazard models on bootstrap samples to construct a multiple gene signatures that maximize area under the curve (AUC) on test samples. We mapped these 76 prognostic genes to GO categories to examine their overlap with the selected gene sets from our analysis. Among the top 20 GO terms selected by SPCA, 9 of them contained genes from the 76-gene signature. However, only one of the top 20 GO terms from GSEA included genes from the 76-gene signature. The most significant GO term selected by SPCA is "Apoptosis", which is known to play an important role in cancer. Two genes from this gene set, TNFSF10 and GAS2, were from the 76-gene signature of Wang et al. (2005) .
GO Term Size Description
To help interpret results from SPCA model, in Figure 2 , for the GO term "apoptosis", we plot loadings 11 12 1 { , ,..., } p α α α for the first principal component score (Section 2.1) using a bar chart. We call these "Important Scores" for the genes: the magnitude and directions of the coefficients represents contributions of each gene to the estimated principal component score or the underlying cellular process approximated by the first principal component score.
Mouse lesion score data
We next applied the proposed SPCA model to an eQTL study. In this section, we illustrate the proposed method for a microarray data set with continuous outcome lesion scores, and we show this method can efficiently account for the design of experiment, by testing for interaction effects and accounting for covariate information.
To identify genetic factors associated with atherosclerosis, Bhasin et al. (2008) conducted eQTL analysis using bone-marrow derived macrophages from F 2 mice obtained by a strain intercross between aopE-deficient mice on the AKR and DBA/2 backgrounds. The apoE-deficient mouse model was created by gene targeting through homologous recombination in embryonic stem cells. These mice spontaneously develop aortic lesions on a low-fat chow diet. The continuous outcome for this study was lesion score, which was used as a measure of severity for atherosclerosis. Our main objective was to identify gene sets associated with variations in lesion scores.
Affymetrix 430v2 expression data from 93 female and 114 male mice were used for this experiment (GEO Accession No. GSE8512). Each sample had 22174 expressed transcripts. After mapping these transcripts to EntrezGene ID and associating them with GO Biological Process categories, there were 9744 genes, mapped to 255 GO categories.
It has been shown that mouse atherosclerotic lesion areas QTLs are sexually dimorphic (Smith et al. 2006) . In this eQTL analysis only 1% trans eQTLs were shared by both sexes, and 31% of expressed transcripts were expressed at different levels in males vs. females (Bhasin et al, 2008) . Therefore, for methods such as GSEA or Fisher's exact test, gene sets can only be analyzed separately using samples from each sex. In contrast, for the proposed method, we can test whether the association between first principal component of the gene set with lesion score is similar for the two groups by testing interaction effect Sex × PC1(supervised first principal component score of the gene set, see Section 2.2). In particular, for each gene set, we fit linear model with outcome log(lesion score), fixed effects Sex, PC1, Sex × PC1. In addition, we specify separate residual variances for each sex to allow for different variations in lesion scores for the two groups. When Sex × PC1 interaction was not significant for a gene set, samples from male and female were pooled to gain more power, otherwise we conducted test for the gene set separately for males and females using Model 1 in Section 2.2.
For gene sets with significant Sex × PC1 interaction effect (at FDR 0.1 level), we constructed separate null distributions for
2) for male samples and female samples. For example, for male samples, we estimated mean and variance of log(lesion scores) using only male samples and then generated pseudo lesion scores from normal distribution with this estimated mean and variance. Next, with these pseudo outcomes, the steps outlined in Sections 2.2 and 2.3 were followed to calculate p-values for each gene set. Table 4 shows the three most significant gene sets for females and males. These gene sets showed a different expression pattern between females and males, and this sexually dimorphic effect could be due to exposure to the different hormonal milieu in female and male mice.
For gene sets with non-significant Sex × PC1 (at FDR 0.1 level), p-values were estimated using null distributions constructed with all samples. The ten most significant gene sets are listed in Table 5 . Previous studies have implicated these gene sets to be related to cardiovascular diseases. For example, the top one and three gene sets are "electron transport" and "apoptosis". The mechanisms of mitochondrial dysfunction related to atherosclerosis had been proposed. Reactive oxygen species (ROS) are produced by the mitochondrial electron transport chain, and increase production of ROS can result in significant damage to lipids, proteins and mtDNA, which will induce vascular smooth muscle cells apoptosis, leading to the development of atherosclerosis (Liu et al. 2002; Madamanchi and Runge, 2007) . The second most significant gene set is "chloride transport", in which three genes, Slc12a5, Clcn4-2 and Clnsla were among genes in the selected subset. The K-Cl cotransporter had been identified as part of of the SLC12 family and is directly related to ROS generation and oxidative stress (Adragna and Lauf, 2007) .
DISCUSSION
In this article, we have described a new strategy for testing significant association of a priori defined sets of genes with continuous or survival outcomes. Typically, only a subset of genes in the group is associated with a biological process. Therefore, without a gene screening step, when all genes in an a priori defined gene set are used to estimate principal components, performance of gene set analysis method using Model 1 (Section 2.2) would be adversely affected by noisy signals from irrelevant genes, especially when the gene-set size is large. This is because the estimated first principal component is often driven by sources of variation unrelated to outcome; in contrast, Supervised PCA removes irrelevant genes before extracting the desired principal component.
We have shown the proposed method compares favorably with currently available methods, with improved sensitivity and specificity at discriminating gene set associated with outcome from null gene sets, using both simulated and real microarray data. The proposed method operates within well defined statistical framework so that the SPCA model can be easily extended to more complicated designs such as time course experiments and dose response experiments with the use of linear mixed effect models in place of general linear models. In addition, it can be further extended by incorporating other forms of known biological knowledge (Khatri and Draghici, 2005) . For example, ScorePage (Rahnenfuhrer, 2004) integrated information from co-regulation of genes and topology of pathways to test for significance of metabolic pathways; they constructed pathway scores based on co-regulation between pairs of genes weighted by their distance on the pathway graph. Similarly, Draghici et al. (2007) developed impact analysis for signaling pathways that considered crucial factors such as the magnitude of each gene's expression change, their type and position in the given pathway and their interactions. Finally, SEGS (Trajkovski 2008) searched for enriched gene sets constructed by integrating GO annotations with gene-gene interaction data from ENTREZ. Although not within the scope of this paper, future studies based on these aforementioned ideas are being planned to further extend the power and potential of the proposed method.
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